Nevro Corp. (NVRO)
USD 3.74
(-7.65%)
USD 3.74
(-7.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -99.3 Million USD | -0.48% |
| 2022 | -98.83 Million USD | -8.69% |
| 2021 | -90.93 Million USD | -44.68% |
| 2020 | -62.85 Million USD | 34.85% |
| 2019 | -96.47 Million USD | -131.13% |
| 2018 | -41.74 Million USD | -41.12% |
| 2017 | -29.57 Million USD | -28.15% |
| 2016 | -23.08 Million USD | 62.99% |
| 2015 | -62.36 Million USD | -120.33% |
| 2014 | -28.3 Million USD | -12.54% |
| 2013 | -25.15 Million USD | -31.47% |
| 2012 | -19.13 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -24.16 Million USD | 22.38% |
| 2024 Q1 | -32.36 Million USD | -174.57% |
| 2023 Q4 | -11.78 Million USD | 53.88% |
| 2023 Q3 | -25.55 Million USD | 0.31% |
| 2023 FY | -99.3 Million USD | -0.48% |
| 2023 Q1 | -36.32 Million USD | -87.64% |
| 2023 Q2 | -25.63 Million USD | 29.41% |
| 2022 Q4 | -19.35 Million USD | 15.53% |
| 2022 Q2 | -23.79 Million USD | 27.4% |
| 2022 Q1 | -32.76 Million USD | -25.0% |
| 2022 FY | -98.83 Million USD | -8.69% |
| 2022 Q3 | -22.91 Million USD | 3.67% |
| 2021 Q2 | -15.76 Million USD | 29.98% |
| 2021 FY | -90.93 Million USD | -44.68% |
| 2021 Q3 | -46.44 Million USD | -194.64% |
| 2021 Q1 | -22.51 Million USD | -2472.8% |
| 2021 Q4 | -26.21 Million USD | 43.56% |
| 2020 Q4 | -875 Thousand USD | 75.35% |
| 2020 Q3 | -3.54 Million USD | 89.96% |
| 2020 Q2 | -35.36 Million USD | -53.3% |
| 2020 FY | -62.85 Million USD | 34.85% |
| 2020 Q1 | -23.06 Million USD | -97.47% |
| 2019 Q3 | -15.98 Million USD | 39.82% |
| 2019 Q2 | -26.56 Million USD | 37.14% |
| 2019 Q1 | -42.25 Million USD | -391.15% |
| 2019 FY | -96.47 Million USD | -131.13% |
| 2019 Q4 | -11.68 Million USD | 26.92% |
| 2018 Q2 | -8.2 Million USD | 47.77% |
| 2018 Q3 | -9.23 Million USD | -12.63% |
| 2018 Q4 | -8.6 Million USD | 6.86% |
| 2018 FY | -41.74 Million USD | -41.12% |
| 2018 Q1 | -15.7 Million USD | -622.93% |
| 2017 Q2 | -9.93 Million USD | 23.85% |
| 2017 FY | -29.57 Million USD | -28.15% |
| 2017 Q4 | -2.17 Million USD | 50.84% |
| 2017 Q3 | -4.41 Million USD | 55.54% |
| 2017 Q1 | -13.05 Million USD | -108.18% |
| 2016 Q1 | -9.01 Million USD | 31.4% |
| 2016 Q2 | -5.92 Million USD | 34.31% |
| 2016 Q3 | -1.87 Million USD | 68.39% |
| 2016 FY | -23.08 Million USD | 62.99% |
| 2016 Q4 | -6.26 Million USD | -234.88% |
| 2015 Q4 | -13.14 Million USD | 25.78% |
| 2015 Q3 | -17.7 Million USD | 7.65% |
| 2015 Q2 | -19.17 Million USD | -55.4% |
| 2015 Q1 | -12.33 Million USD | -73.64% |
| 2015 FY | -62.36 Million USD | -120.33% |
| 2014 Q1 | -7.24 Million USD | -10.8% |
| 2014 FY | -28.3 Million USD | -12.54% |
| 2014 Q4 | -7.1 Million USD | -9.36% |
| 2014 Q3 | -6.49 Million USD | 12.91% |
| 2014 Q2 | -7.46 Million USD | -3.04% |
| 2013 Q3 | -5.36 Million USD | 13.39% |
| 2013 FY | -25.15 Million USD | -31.47% |
| 2013 Q4 | -6.53 Million USD | -21.88% |
| 2013 Q1 | -7.06 Million USD | 0.0% |
| 2013 Q2 | -6.19 Million USD | 12.35% |
| 2012 FY | -19.13 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 101.533% |
| Allurion Technologies Inc. | -78.07 Million USD | -27.191% |
| Artivion, Inc. | 5.74 Million USD | 1829.502% |
| Avanos Medical, Inc. | 4.2 Million USD | 2464.476% |
| Butterfly Network, Inc. | -145.61 Million USD | 31.799% |
| Butterfly Network, Inc. | -145.61 Million USD | 31.799% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 125.875% |
| Boston Scientific Corporation | 2.34 Billion USD | 104.238% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | -554.117% |
| CONMED Corporation | 130.78 Million USD | 175.932% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 106.473% |
| Paragon 28, Inc. | -37.3 Million USD | -166.177% |
| Glaukos Corporation | -128.7 Million USD | 22.838% |
| Globus Medical, Inc. | 133.14 Million USD | 174.588% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | -146.599% |
| Integer Holdings Corporation | 167.33 Million USD | 159.349% |
| Medtronic plc | 5.14 Billion USD | 101.931% |
| Owlet, Inc. | -28.63 Million USD | -246.843% |
| Penumbra, Inc. | 73.55 Million USD | 235.019% |
| Vicarious Surgical Inc. | -80.66 Million USD | -23.11% |
| Smith & Nephew plc | 425 Million USD | 123.367% |
| Sonendo, Inc. | -57.74 Million USD | -71.983% |
| STERIS plc | 836.11 Million USD | 111.877% |
| Stryker Corporation | 3.88 Billion USD | 102.554% |
| Vapotherm, Inc. | -39.08 Million USD | -154.115% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 107.772% |